Table 1 Significantly enriched metabolic pathways following CCI injury
From: Metabolic-driven analytics of traumatic brain injury and neuroprotection by ethyl pyruvate
Enriched pathways | Holm | FDR | Impact | Metabolite hits |
|---|---|---|---|---|
Glutathione metabolism | 4.0E−11 | 2.6E−11 | 0.038 | Glutathione disulfide; l-Cysteine; Acetyl-CoA; Putrescine |
Glycine, serine and threonine metabolism | 5.0E−11 | 2.6E−11 | 0.095 | Betaine; Guanidinoacetate; l-Cystathionine; l-Threonine; l-Cysteine |
Glycolysis/gluconeogenesis | 5.8E−09 | 2.0E−09 | 0.042 | Acetyl-CoA; beta-d-Glucose |
Arginine and proline metabolism | 9.0E−09 | 2.4E−09 | 0.332 | Guanidinoacetate; GABA; Agmatine; Putrescine; N-Acetylputrescine; Hydroxyproline; l-Proline; 4-Acetamidobutanoate; Homocarnosine; |
Pyrimidine metabolism | 7.4E−08 | 1.6E−08 | 0.207 | dCMP; Deoxycytidine; Thymidine; Thymine; N-Carbamoyl-l-aspartate; Orotate |
Lysine degradation | 9.3E−08 | 1.7E−08 | 0.141 | L-2-Aminoadipate; l-Pipecolate; Acetyl-CoA |
Arginine biosynthesis | 3.1E−07 | 4.1E−08 | 0.228 | l-Citrulline; ⍺-Ketoglutarate |
Taurine and hypotaurine metabolism | 5.9E−07 | 7.3E−08 | 0.286 | l-Cysteine; Hypotaurine |
Alanine, aspartate and glutamate metabolism | 2.3E−06 | 2.3E−07 | 0.221 | N-Acetyl-l-aspartate; l-Alanine; GABA; Citrate; N-Carbamoyl-l-aspartate; ⍺-Ketoglutarate |
Butanoate metabolism | 7.0E−06 | 6.6E−07 | 0.032 | Acetyl-CoA; GABA; ⍺-Ketoglutarate |
Cysteine and methionine metabolism | 7.9E−06 | 7.2E−07 | 0.274 | l-Cystathionine; l-Cysteine; Ophthalmate |
Tryptophan metabolism | 1.5E−05 | 1.3E−06 | 0.108 | 5-Hydroxyindoleacetate; l-Kynurenine; Acetyl-CoA |
Valine, leucine and isoleucine degradation | 1.0E−04 | 8.7E−06 | 0.028 | Acetyl-CoA; l-Valine; l-Isoleucine |
Citrate cycle (TCA cycle) | 2.3E−04 | 1.8E−05 | 0.186 | ⍺-Ketoglutarate; Acetyl-CoA; citrate |
Amino sugar and nucleotide sugar metabolism | 3.1E-−04 | 2.5E−05 | 0.081 | d-Mannose 6-phosphate; beta-d-Fructose |